2026-01-27 - Analysis Report
**Company Overview**
Amgen is a biotechnology company that develops and commercializes pharmaceuticals and biologics to treat various diseases.

**Return Rate Comparison**
| Ticker | Cumulative Return |
|--------|--------------------|
| AMGN   | 93.67%             |
| VOO    | 127.58%            |
| Difference in Cumulative Return on Last Day of Data | -33.91% |

The cumulative return of AMGN is 73.91% lower than VOO on the last day of the data, indicating a divergence of -33.91%.

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta |
|------------|------|------|-------|-------|
| 2016-2018  | 20.0% | 16.1% | 11.0% | 1.1   |
| 2017-2019  | 45.0% | 12.1% | 20.0% | 0.9   |
| 2018-2020  | 18.0% | 21.8% | -6.0% | 0.8   |
| 2019-2021  | 15.0% | 21.8% | -49.0%| 0.8   |
| 2020-2022  | 18.0% | 19.4% | 13.0% | 0.6   |
| 2021-2023  | 21.0% | 20.6% | 3.0%  | 0.4   |
| 2022-2024  | 15.0% | 21.2% | -15.0%| 0.4   |
| 2023-2025  | 38.0% | 21.3% | -38.0%| 0.5   |

### Trends
CAGR (Compound Annual Growth Rate) shows mixed results, ranging from 15% to 45%. MDD (Maximum Drawdown) shows high drawdowns in some years, with a maximum of 21.8%. Alpha, representing the excess return of AMGN over the S&P 500, is generally positive, with a maximum of 20.0% and a minimum of -49.0%. Beta, representing the volatility of AMGN, is relatively low, ranging from 0.4 to 1.1.

### Market Value
The market capitalization of AMGN has increased over the years, ranging from 104.8B USD in 2016-2018 to 176.2B USD in 2023-2025.

### Stock Price Fluctuations
| Figure  | Value |
|--------|-------|
| 5-day SMA | $343.22 |
| 20-day SMA | $332.51 |
| 60-day SMA | $328.72 |

The stock price is currently above all moving averages, indicating an upward trend.

**RSI, PPO, and Delta_Previous_Relative_Divergence**
| Indicator | Value |
|-----------|-------|
| RSI       | 71.21 |
| PPO       | 0.64  |
| MRI       | 0.70  |
| Delta_Previous_Relative_Divergence| 9.50 (+) |
|7-day Rank change | -23 (-) |
| 7-day Dynamic Expected Return change | -28.90 (-) |
| Expected Return (%) | -30.90% |

The RSI value is high at 71.21, indicating an overbought condition. The PPO value is low at 0.64, indicating a bearish signal. The MRI value is 0.70, indicating a medium-risk investment. The Delta_Previous_Relative_Divergence value is positive at 9.50, indicating an improving trend. The 7-day Rank change and 7-day Dynamic Expected Return change are both negative, indicating a decrease in rank and expected return. The Expected Return value is negative at -30.90%, indicating a long-term excess return compared to the S&P 500.

**Recent News & Significant Events**

The recent news articles indicate a positive sentiment towards Amgen, with analyst upgrades and price targets being raised.

*   Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks
*   Intact Investment Management Inc. Cuts Stock Position in Amgen Inc. $AMGN
*   UBS Raises Price Target for Amgen (AMGN) Following Recent Analysis
*   Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
*   Amgen stock hits 52-week high at $346.41

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.41 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 331.96 / 425.00 / 180.00

The analyst consensus is overwhelmingly positive, with 27 opinions calling for a buy.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|------|-----|---------|
| 2025-11-05 | 5.98 | 9.56 B$ |
| 2025-08-06 | 2.66 | 9.18 B$ |
| 2025-05-02 | 3.22 | 8.15 B$ |
| 2024-10-31 | 5.27 | 8.50 B$ |
| 2025-11-05 | 5.27 | 8.50 B$ |

### Trends
EPS has been steadily increasing over the past two quarters, with a maximum of 5.98 in 2025-Q3. Revenue has also been increasing, with a maximum of 9.56 billion USD in 2025-Q3.

### Profitability
The profit margin has been relatively steady, ranging from 61.07% to 67.75%. The return on equity (ROE) has been increasing over the past two quarters, with a maximum of 37.60% in 2024-Q3.

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

### Trends
Revenue has been steadily increasing over the past two years, with a maximum of 9.56 billion USD in 2025-Q3. Profit margin has been relatively steady, ranging from 61.07% to 67.75%.

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

### Trends
Equity has been steadily increasing over the past two years, with a maximum of 9.62 billion USD in 2025-Q3. ROE has also been increasing over the past two years, with a maximum of 37.60% in 2024-Q3.

**Comprehensive Analysis**

Amgen has a mixed performance record, with high return rates in some years and significant drawdowns in others. The company's stock price is currently above all moving averages, indicating an upward trend. The RSI value is high at 71.21, indicating an overbought condition. The PPO value is low at 0.64, indicating a bearish signal. The MRI value is 0.70, indicating a medium-risk investment. The recent news articles indicate a positive sentiment towards Amgen, with analyst upgrades and price targets being raised. The analyst consensus is overwhelmingly positive, with 27 opinions calling for a buy. The company's revenue and profitability have been steadily increasing over the past two years, with a maximum of 9.56 billion USD in revenue and 37.60% return on equity in 2024-Q3.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.